leadf
logo-loader
viewZelira Therapeutics Ltd
(
ASX:ZLDOTCQB:ZLDAF
)

Zelira Therapeutics forms exclusive licensing deal to distribute its HOPE products in Washington DC

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Managing Directors Dr Oludare Odumosu and Dr Richard Hopkins tell Proactive the group has entered into a binding licensing agreement with Alternative Solutions LLC to manufacture and distribute Zelira’s HOPE products in the Washington DC approved medical cannabis market.

Dr Odumosu and Dr Hopkins explain Washington DC is a gateway territory, with over 24 million visitors passing through each year. Alternative Solutions will commercialize Zelira’s HOPE products for sale in the second quarter of 2021.

Quick facts: Zelira Therapeutics Ltd

Follow
ASX:ZLD

Price: 0.043 AUD

Market Cap: $51.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics enters German market through an exclusive cannabis...

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) (ASX:ZLD) (OTCQB:ZLDAF) Managing Director Dr Oludare Odumosu tells Proactive the group has expanded into Europe via the large and growing German cannabinoid-based medicines market through an exclusive distribution agreement with Adjupharm GmbH, a...

2 days, 21 hours ago

2 min read